In addition, in vivo studies utilizing a ROR agonist, nobiletin, have reported blood glucose lowering effects in rodent models of obesity, but mechanisms of ROR regulation of gluconeogenesis are yet to be determined (123). Here, LINC-ROR is linked to obesity disorder.